Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR1D | P28221 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 3/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506665 | 0.76 | DRD2 (0.37) | DRD2HTR1DDRD3 | |
| SCHEMBL9085508 | 0.76 | HTR2A (0.35) | MEN1KMT2ADRD2HTR1DDRD3 | |
| SCHEMBL837149 | 0.74 | KMT2A (0.56) | MEN1KMT2ACA1CA2 | |
| SCHEMBL19330608 | 0.74 | CXCR2 (0.38) | DRD2HTR1DDRD3METAP2 | |
| SCHEMBL19249620 | 0.73 | DRD2 (0.35) | DRD2HTR1DDRD3 | |
| SCHEMBL12533492 | 0.71 | DRD2 (0.38) | DRD2HTR1DDRD3 | |
| SCHEMBL6411328 | 0.71 | CXCR2 (0.40) | DRD2HTR1DDRD3METAP2 | |
| SCHEMBL7030007 | 0.71 | DRD2 (0.41) | DRD2HTR1DDRD3 | |
| SCHEMBL3113928 | 0.71 | DRD2 (0.53) | DRD2HTR1DDRD3 | |
| SCHEMBL1506403 | 0.70 | STS (0.34) | MEN1KMT2ADRD2HTR1DDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | REN, ALPI, IKBKE | MEN1 4515/4885KMT2A 3883/4885DRD2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.